Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506 | 1.00 | HDAC1 (0.35) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL2732664 | 0.81 | HDAC1 (0.41) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL2732662 | 0.81 | HDAC1 (0.41) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL30077 | 0.75 | HDAC1 (0.48) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL30078 | 0.75 | HDAC1 (0.48) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL6898783 | 0.73 | HDAC1 (0.37) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL29508 | 0.72 | LMNA (0.37) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL29505 | 0.72 | LMNA (0.37) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL2731322 | 0.71 | HDAC1 (0.41) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL2731321 | 0.71 | HDAC1 (0.41) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | claimed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | claimed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | claimed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC8 8/4885HDAC3 3/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC8 8/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.